Daiwa Securities Group Inc. Sells 17,798 Shares of Biogen Inc. $BIIB

Daiwa Securities Group Inc. lowered its position in Biogen Inc. (NASDAQ:BIIB) by 40.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,277 shares of the biotechnology company’s stock after selling 17,798 shares during the quarter. Daiwa Securities Group Inc.’s holdings in Biogen were worth $4,624,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of Biogen during the fourth quarter valued at $464,408,000. Orion Porfolio Solutions LLC raised its holdings in shares of Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after acquiring an additional 509,809 shares in the last quarter. Caisse de depot et placement du Quebec raised its holdings in shares of Biogen by 718.2% in the third quarter. Caisse de depot et placement du Quebec now owns 569,253 shares of the biotechnology company’s stock valued at $79,741,000 after acquiring an additional 499,676 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Biogen by 30.7% in the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after acquiring an additional 418,776 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its holdings in shares of Biogen by 66.1% in the third quarter. Alyeska Investment Group L.P. now owns 845,277 shares of the biotechnology company’s stock valued at $118,406,000 after acquiring an additional 336,504 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Guggenheim lifted their price objective on Biogen from $246.00 to $260.00 and gave the company a “buy” rating in a report on Thursday, April 30th. TD Cowen lifted their price objective on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a report on Monday, February 9th. Citigroup lifted their price objective on Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Oppenheimer lifted their price objective on Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Finally, Freedom Capital upgraded Biogen from a “hold” rating to a “strong-buy” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Biogen has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

Biogen Price Performance

Shares of BIIB stock opened at $192.62 on Tuesday. Biogen Inc. has a fifty-two week low of $121.05 and a fifty-two week high of $205.97. The firm has a market capitalization of $28.44 billion, a price-to-earnings ratio of 20.67 and a beta of 0.20. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock’s 50-day simple moving average is $187.63 and its 200-day simple moving average is $183.63.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the firm earned $3.02 earnings per share. The company’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts forecast that Biogen Inc. will post 14.18 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.